Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomized, placebo-controlled phase 2 study.

Santoro, A; Rimassa, L; Borbath, I; Daniele, B; Salvagni, S; Van Laethem, J L; Van Vlierberghe, H; Trojan, J; Kolligs, F T; Weiss, A; Miles, S; Gasbarrini, A; Lencioni, M; Cicalese, L; Sherman, M; Gridelli, C; Buggisch, P; Gerken, G; Schmid, R M; Boni, C; Personeni, N; Hassoun, Z; Abbadessa, G; Schwartz, B; Von Roemeling, R; Lamar, M E; Chen, Y; Porta, C